InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by Bolte Axel, Chairman & CEO. Director active across 2 companies, notably Inozyme Pharma, Inc.. Cumulatively, 4 filings have been logged. Total volume traded: €232k. The latest transaction was disclosed on 19 April 2022 — Acquisition. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations4 total
7,500 shares
Common Stock
SEC:0001410939-22-000069:0·
€231,59867,750 shares@ €3.418467.9% of flow
Common Stock
SEC:0001209191-22-024917:0·
Ideal exit: 14 Jan 2023 (T+270)
€54,86266,788 shares@ €0.8214100.0% of flow
Common Stock
SEC:0001209191-21-043205·
€54,86266,788 shares@ €0.821416.1% of flow
Common Stock
SEC:0001209191-21-043205:0·
4 of 4 declarations
About Bolte Axel
Axel Bolte is the Chairman & CEO of Inozyme Pharma, Inc. and IVERIC bio, Inc. He leads these companies with a strategic vision focused on innovation and expansion. His leadership is essential for developing therapeutic solutions in the biopharmaceutical sector.
